Summary
In nature, all biological material from the cell to the tissue level is subjected to continuous mechanical stress and strain. These mechanical cues play an essential role on several biological processes and can determine the fate of a healing or a cancerous process, among many others. Therefore, research activities focusing on studying the deterministic nature of these processes need a robust test platform that allows for reproducing these mechanically-varying environments. Such a system would significantly contribute to improving in-vitro testing of therapies and drug discovery, incorporating the essential influence of mechanics in pharmaceutical and biotechnological companies. However, the current approaches are restricted to basic science methods with important limitations. This lack of a suitable system hinders the translation of basic science in mechanobiology to its application in the industrial-technological field. ISBIOMECH proposes a novel intelligent system to control the mechanical environment of cellular/tissue materials, to be commercially exploited as laboratory equipment for mechanobiology research and pathological treatment testing. The novel device and associated software will provide the first commercially available system to allow for robust and reproducible in-vitro testing of mechanically-influenced biological processes. More concretely, the system will use magneto-responsive substrates allowing for non-invasive, multidimensional and real-time control of complex deformation modes on cellular/tissue materials. This technology will be implemented and validated by demonstration activities at stakeholders’ labs to address timely mechanobiological studies in epithelial wound healing, neurological disorders and cardiac pathology. The proposed system has the potential to open the experimental path to improve current treatments in, e.g., cancer pathologies, pathological skin scarring or fibrotic heart remodelling during myocardial infarction.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101081713 |
| Start date: | 01-06-2023 |
| End date: | 30-11-2024 |
| Total budget - Public funding: | - 150 000,00 Euro |
Cordis data
Original description
In nature, all biological material from the cell to the tissue level is subjected to continuous mechanical stress and strain. These mechanical cues play an essential role on several biological processes and can determine the fate of a healing or a cancerous process, among many others. Therefore, research activities focusing on studying the deterministic nature of these processes need a robust test platform that allows for reproducing these mechanically-varying environments. Such a system would significantly contribute to improving in-vitro testing of therapies and drug discovery, incorporating the essential influence of mechanics in pharmaceutical and biotechnological companies. However, the current approaches are restricted to basic science methods with important limitations. This lack of a suitable system hinders the translation of basic science in mechanobiology to its application in the industrial-technological field. ISBIOMECH proposes a novel intelligent system to control the mechanical environment of cellular/tissue materials, to be commercially exploited as laboratory equipment for mechanobiology research and pathological treatment testing. The novel device and associated software will provide the first commercially available system to allow for robust and reproducible in-vitro testing of mechanically-influenced biological processes. More concretely, the system will use magneto-responsive substrates allowing for non-invasive, multidimensional and real-time control of complex deformation modes on cellular/tissue materials. This technology will be implemented and validated by demonstration activities at stakeholders’ labs to address timely mechanobiological studies in epithelial wound healing, neurological disorders and cardiac pathology. The proposed system has the potential to open the experimental path to improve current treatments in, e.g., cancer pathologies, pathological skin scarring or fibrotic heart remodelling during myocardial infarction.Status
SIGNEDCall topic
ERC-2022-POC2Update Date
31-07-2023
Images
No images available.
Geographical location(s)
Structured mapping
